Skip to main content
. Author manuscript; available in PMC: 2018 Dec 26.
Published in final edited form as: Int J Gynecol Pathol. 2019 Jan;38(Suppl 1):S64–S74. doi: 10.1097/PGP.0000000000000518

Figure 4. Harnessing The Cancer Genome Atlas (TCGA) data for clinical diagnosis.

Figure 4

EMC: endometrial carcinoma; MSI-H: microsatellite instability high; CN-L: copy number low (type I EMC); POLE: polymerase E hotspot mutant tumor; CN-H: copy number high (serous or serous-like endometrial carcinoma)

*EMC: This may also be applicable to clear cell carcinomas. Most cases can be separated with review of hematoxylin and eosin slides; **EMC: This assay does not distinguish CN-H grade 3 endometrioid carcinoma or CN-H clear cell carcinoma from serous carcinoma